drugset / Trial / NCT00696761

The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients

NCT00696761

Phase 4 Completed 232 enrolled Asan Medical Center
RandomizedParallel-groupOpen-labelTreatment

Summary

Benign prostatic hyperplasia (BPH) is a common condition among older men. The efficacy of α1-blockers for treating BPH has been well documented and they are recommended for the treatment of BPH by clinical guidelines. It is not well known if a stratification based on the grade of BOO and bladder contractility has any predictive value for patients who are treated with an α1-selective blocking agent. In our study, we investigated possible differences in treatment outcome between patients with and without BOO, and with or without proper contractility who are treated with alfuzosin. So we will compare the quantified improvements 12 months after alfuzosin medication in LUTS/BPH patients by the grade of BOO and/or bladder contractility.

Timeline

Start
2006-05
Primary completion
2008-07
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alfuzosin Small molecule 10 mg